Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Lactate controls glomerular endothelial barrier integrity in lupus nephritis
Jiaxin Lei, Xingyu Zhai, Yixin Wang, Ying Li, Lei Li, Mengdi Liu, Jing Guo, Lingyi Li, Zhezhuyun Chen, Qinghua Cao, Zhichun Liu, Ting Liu, Lin Xu, Zhenke Wen
Jiaxin Lei, Xingyu Zhai, Yixin Wang, Ying Li, Lei Li, Mengdi Liu, Jing Guo, Lingyi Li, Zhezhuyun Chen, Qinghua Cao, Zhichun Liu, Ting Liu, Lin Xu, Zhenke Wen
View: Text | PDF
Research Article Nephrology

Lactate controls glomerular endothelial barrier integrity in lupus nephritis

  • Text
  • PDF
Abstract

Systemic lupus erythematosus (SLE) is a progressive autoimmune disease that affects multiple organs and tissues, with lupus nephritis (LN) as one of its most severe complications. Although LN progression is associated with compromised permeability of human renal glomerular endothelial cells (HRGECs), the underlying mechanisms are not fully defined. Herein, we demonstrate that aberrant glycolysis drives this glomerular endothelial barrier defect by suppressing the transcription of tight junction (TJ) genes. Mechanistically, circulating self-DNA in SLE plasma acts as a ligand that activates the cGAS/STING pathway in HRGECs, driving aberrant glycolytic adaption. The resulting glycolytic product, lactate, serves as a substrate for protein lactylation, leading to extensive lactylation and subsequent ubiquitination of enhancer of zeste homolog 2 (EZH2). In consequence, EZH2 deficiency results in reduced H3K27me3 levels, thereby suppressing the transcription of TJ genes. In a self-DNA–induced SLE model, inhibition of cGAS/STING signaling or lactate production effectively restored the integrity of TJs of HRGECs and concurrently alleviated key LN symptoms. Together, lactate programs lactylation and ubiquitination of EZH2 to impair the glomerular endothelial barrier in human SLE.

Authors

Jiaxin Lei, Xingyu Zhai, Yixin Wang, Ying Li, Lei Li, Mengdi Liu, Jing Guo, Lingyi Li, Zhezhuyun Chen, Qinghua Cao, Zhichun Liu, Ting Liu, Lin Xu, Zhenke Wen

×

Figure 5

Lactate-induced EZH2 lactylation facilitates its ubiquitination through enhanced RACK1 interaction.

Options: View larger image (or click on image) Download as PowerPoint
Lactate-induced EZH2 lactylation facilitates its ubiquitination through ...
(A) IP analysis was performed to detect EZH2 lactylation in HRGECs after 24 hours’ treatment with 10% plasma from HC or SLE individuals. (B) HRGECs were cultured in the presence or absence of lactate (40 mM) for 24 hours, and EZH2 lactylation was subsequently analyzed via IP. (C) IP analysis was conducted to assess EZH2 lactylation in HEK293T cells cotransfected with HA-EZH2 and the indicated acetyltransferase. (D) Co-IP analysis was used to examine the interaction between EZH2 and PACF in HRGECs. (E) IP analysis was conducted to assess EZH2 lactylation in HEK293T cells transfected with Flag-EZH2 (WT) or the indicated EZH2 mutants. (F–J) HRGECs were transfected with shRNA targeting PCAF or nontargeting control shRNA, then treated with SLE plasma for 24 hours. (F) Co-IP analysis was used to examine the interaction between EZH2 and RACK1. (G) IP analysis was conducted to assess EZH2 ubiquitination. (H) Western blot was employed to evaluate H3K27me2 levels. qPCR (I) and Western blot (J) were conducted to assess the expression levels of TJ-related proteins. Mean ± SEM from 6 independent individuals (I). (K) Co-IP analysis was conducted to assess the interaction between EZH2 and RACK1 in HEK293T cells transfected with Flag-EZH2 (WT) or Flag-EZH2K245R mutants. (L) IP was performed to evaluate EZH2 ubiquitination in 40 mM lactate-treated HEK293T cells transfected with Flag-EZH2 (WT) or the Flag-EZH2 (K245R) mutant. ***P < 0.001 and ****P < 0.0001 with 2-way ANOVA plus Tukey’s method (I).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts